Analyst Price Targets — ORIC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 3:50 pm | Robert Burns | H.C. Wainwright | $25.00 | $13.27 | TheFly | Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright |
| February 24, 2026 5:34 am | Matthew Biegler | Oppenheimer | $15.00 | $11.71 | StreetInsider | Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC) |
| January 7, 2026 10:19 am | Kelsey Goodwin | Piper Sandler | $22.00 | $8.14 | TheFly | Oric Pharmaceuticals initiated with an Overweight at Piper Sandler |
| December 8, 2025 11:15 am | — | Wells Fargo | $25.00 | $11.00 | TheFly | Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo |
| November 14, 2025 3:58 pm | — | H.C. Wainwright | $23.00 | $12.78 | TheFly | Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright |
| September 4, 2025 9:21 am | Brad Canino | Guggenheim | $18.00 | $10.60 | TheFly | Oric Pharmaceuticals assumed with a Buy at Guggenheim |
| May 6, 2025 11:45 am | Matthew Biegler | Oppenheimer | $12.00 | $5.04 | TheFly | Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer |
| September 5, 2024 4:13 pm | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | TheFly | Oric Pharmaceuticals initiated with a Buy at Stifel |
| March 21, 2024 6:32 am | Robert Burns | H.C. Wainwright | $21.00 | $14.59 | StreetInsider | ORIC Pharamceuticals (ORIC) PT Raised to $21 at H.C. Wainwright following 2023 results |
| March 12, 2024 12:55 pm | David Nierengarten | Wedbush | $20.00 | $14.63 | Benzinga | These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results |
Latest News for ORIC
Executives from Oric Pharmaceuticals (NASDAQ: ORIC) used a conference discussion to highlight near-term clinical catalysts for its two lead oncology programs and to outline how upcoming data could shape development plans in prostate and lung cancer. Company focus and clinical-stage pipeline Management described Oric as a clinical-stage oncology company with a focus on prostate cancer, lung
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the “Grant Date”), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORIC.
U.S. House Trading
No House trades found for ORIC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.